secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0001193125-25-029591
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share
--------------------------------------------------------------------------------

- Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.
- Proceeds to fund R&D activities, including clinical development of casdatifan, manufacturing, and general corporate purposes.
- Offering closed on Feb 19, 2025; underwritten by Goldman Sachs and Leerink Partners.
- Shares sold under existing shelf registration statement (Form S-3) filed with the SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000119312525029591/0001193125-25-029591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000119312525029591/d932072d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-029591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer